A Phase 1 interventional study of AZD7798 and Placebo in Healthy Subjects and Crohns Disease, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Crohn Disease by AstraZeneca — none open to participants now, 2 under way, none of them phase 3. Crohn Disease · AstraZeneca.
Among the 13 studies in Crohn Disease by AstraZeneca, this one is the 4th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 1, and was the 9th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →None of the 13 studies in Crohn Disease by AstraZeneca is open now. The open studies under Crohn Disease, anywhere →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 3
First in 2006; this study’s year is marked. 1 started in 2022.
This study's enrollment of 112 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 48 across the 13 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Crohn Disease by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety, tolerability, immunogenicity, and pharmacokinetics (PK), and explore the pharmacodynamics (PD) following single ascending dose administration and repeat dose administration in healthy subjects and patients with Crohn's disease.
This is a Phase I, randomised, double-blind, placebo controlled study in healthy male and female subjects as well as patients with Crohn's disease performed at a single study centre.
This study is comprised of 3 parts: Part 1 (sub-parts 1a and 1b), Part 2, and Part 3 (sub-Parts 3a and 3b).
Part 2: Up to 8 patients will be randomised (2:1:1) into 1 of 3 strata and receive:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Study Parts:
Part 1 (Healthy Subjects), Part 3a (Healthy Japanese Subjects) and Part 3b (Healthy Chinese Subjects):
Part 1a (in case of dose escalation in patients) and Part 2 (Patients with Crohn's Disease):
Active disease, defined by at least one symptom and sign consistent with Crohn's disease AND at least one of the following:
Part 3a (Japanese Subjects) • Subject is a native of Japan; defined as having both parents and 4 grandparents who are Japanese. This includes second and third generation subjects of Japanese descent whose parents or grandparents are living in a country other than Japan.
Part 3b (Chinese Subjects)
Healthy Chinese subjects. Subjects of Chinese ancestry are eligible based on meeting all of the following:
Exclusion Criteria:
All Study Parts:
Part 1 (Healthy Subjects), Part 3a (Japanese Subjects, and Part 3b (Chinese Subjects):
Part 1a (in case of dose escalation in patients) and Part 2 (Patients with Crohn's Disease):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A total of 6 subjects will receive single ascending doses of AZD7798.
Biological: AZD7798
A total of 6 subjects will receive single ascending doses of AZD7798.
Biological: AZD7798
A total of 6 subjects will receive single ascending doses of AZD7798.
Biological: AZD7798
A total of 6 subjects will receive single ascending doses of AZD7798.
Biological: AZD7798
A total of 6 subjects will receive single ascending doses of AZD7798.
Biological: AZD7798
A total of 6 subjects will receive single ascending doses of AZD7798.
Biological: AZD7798
A total of 6 subjects will receive single ascending doses of AZD7798.
Biological: AZD7798
A total of 6 subjects will receive repeat doses of AZD7798.
Biological: AZD7798
A total of 6 subjects will receive a single ascending dose of AZD7798.
Biological: AZD7798
A total of 4 subjects will receive a single dose on Day 1 followed by a single dose on Day 15.
Biological: AZD7798
A total of 2 subjects will receive placebo on day 1 followed by AZD7798 on day 15.
Biological: AZD7798
A total of 2 subjects will receive AZD7798 on day 1 followed by placebo on day 15.
Biological: AZD7798
A total of 2 subjects per cohort will receive placebo.
Biological: Placebo
A total of 6 subjects will receive single ascending doses of AZD7798.
Biological: AZD7798
A total of 6 subjects will receive single ascending doses of AZD7798.
Biological: AZD7798
A total of 2 subjects per cohort will receive placebo.
Biological: Placebo
Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.
Subjects will receive placebo matching the AZD7798 dose as a single ascending dose or as a repeat dose.
Number of participants with Adverse Events (AEs)
The safety and tolerability of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Until follow-up (Day 85) or Early termination (ET)
Area under plasma concentration time curve from zero to infinity (AUCinf)
The AUCinf of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
AUClast
The AUClast of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Maximum serum concentration (Cmax)
The Cmax of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Time to reach maximum serum concentration (tmax)
The tmax of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Time to last measurable concentration (tlast)
The tlast of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Terminal elimination half-life (t½λz)
The t½λz of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Systemic clearance (CL)
The CL of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Apparent total clearance (CL/F)
The CL/F of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Volume of distribution based on the terminal phase (Vz)
The Vz of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Apparent volume of distribution based on terminal phase (Vz/F)
The Vz/F of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Bioavailability (F)
The F of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Volume of distribution at steady state (Vss)
The Vss of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
AUClast/D
The AUClast/D of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
AUCinf/D
The AUCinf/D of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Cmax/D
The Cmax/D of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Percentage of patients with antidrug antibodies (ADAs)
The immunogenicity of AZD7798 following administration of single ascending doses will be assessed.
Time frame: Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2022 to primary completion in Nov 2024, 28 months.
Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 28 months is above that.
Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD7798